Tag:

Johnson & Johnson

Latest Headlines

Latest Headlines

Could Gilead's $95K nod trigger creative payment ideas? Ask J&J and AbbVie

Alarmed payers are gearing up for another hepatitis C battle. Now that Gilead Sciences' new two-in-one infection fighter Harvoni is approved--and with a $94,500 price--it's worth looking at some strategies payers have used with other hep C drugs, including Sovaldi, the single-agent sibling to Harvoni.

J&J beats the Street for Q3, thanks to surging sales of standout drugs

Johnson & Johnson is riding the tailwinds of recent success, celebrating positive third quarter earnings buoyed by record-setting sales of its top products and the sell-off of its Ortho-Clinical Diagnostics business.

Forest, Otsuka and J&J spend the most on fees and food for doctors

The Sunshine Act data's been out in the open for a couple of days now (well--most of it), and despite the database's clunkiness, the number crunching is well underway. The Wall Street Journal, for one, has broken down which pharma companies topped the doc-paying list in a variety of different spending categories.

J&J makes a splash in hep C with a $1.75B deal for Alios

Johnson & Johnson is taking a deep dive into antivirals, trading $1.75 billion for private biotech Alios BioPharma to get its hands on a midstage treatment and some early assets that could expand its share of the blockbuster hepatitis C market.

Overseas limits on J&J's Olysio use might signal trouble back home

Johnson & Johnson pessimists are already worried that Olysio will have a short, happy, busy life and an all-too-sudden end.

J&J 'disappointed' U.K. watchdogs nixed Olysio-Sovaldi hep C combo. What next?

Johnson & Johnson pessimists are already worried that Olysio will end up like a mayfly, with a short, happy, busy life and an all-too-sudden end. If the U.K.'s cost-effectiveness gatekeepers offer any indication, they may be correct.

J&J trims pension benefits for new hires

Even drugmakers with steamrolling pharma units need to cut costs sometimes, and Johnson & Johnson fits that bill. To do so, the company will shrink the pension benefits offered to those who are hired--or rehired--after January 1.

J&J ordered to fork over $3M in vaginal mesh case

Johnson & Johnson's Ethicon unit lost a battle in its ongoing vaginal mesh litigation as a federal jury in West Virginia ordered the company to pay $3.27 million to a woman who claimed the device caused undue pain and serious side effects.

The metal-on-metal hip legal saga round one (of 6,000?): J&J vs. Herlihy-Paoli

Johnson & Johnson squared off with aggrieved metal-on-metal hip customer Kathleen Herlihy-Paoli in a case that the plaintiffs says could lead to a $5 billion-plus payout. Herlihy-Paoli's claims that the hips leaked metal into her bloodstream, leading to an infection that required the artificial hip to be removed.  

FDA rushes J&J, NewLink Genetics Ebola vaccines to clinical trials

Another Big Pharma player is joining the hustle toward an Ebola vaccine as the death toll surpasses 1,900 victims, eclipsing the total number of people who died from the disease in all previous outbreaks combined.